A variety of approaches to target these anti-apoptotic oncoproteins have been pursued in order to try and restore the natural process of programmed cell death [14], notably bcl-2 anti-sense oligonucleotides such as Oblimersen (Genasense®) with contrasted positive [15], [16] or negative [17]–[19] impact in randomized clinical trials performed in cutaneous melanoma, chronic lymphoid leukemia, multiple myeloma, and prostate cancer patients. This evidence concerns the gene BCL2 and plasma cell myeloma.